Symbol="ARGX"
AssetType="Common Stock"
Name="argenx NV ADR"
Description="argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands."
CIK="1697862"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="INDUSTRIEPARK ZQIJNAARDE 7, BUILDING C B-9052, ZWIJNAARDE, BE"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="21211611000"
EBITDA="-479285760"
PERatio="None"
PEGRatio="0"
BookValue="2.032"
DividendPerShare="0"
DividendYield="0"
EPS="-9.17"
RevenuePerShareTTM="0.463"
ProfitMargin="-0.8"
OperatingMarginTTM="-0.946"
ReturnOnAssetsTTM="-0.151"
ReturnOnEquityTTM="-0.265"
RevenueTTM="639411000"
GrossProfitTTM="-251786000"
DilutedEPSTTM="-9.17"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="6.3"
AnalystTargetPrice="474"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="78.22"
PriceToBookRatio="7.24"
EVToRevenue="72.3"
EVToEBITDA="-21.25"
Beta="0.429"
num_52WeekHigh="423.99"
num_52WeekLow="333.07"
num_50DayMovingAverage="395.72"
num_200DayMovingAverage="378.7"
SharesOutstanding="55956000"
DividendDate="None"
ExDividendDate="None"
symbol="ARGX"
open="377.68"
high="380.86"
low="372.95"
price="379.08"
volume="486088.00"
latest_trading_day="2023-07-14"
previous_close="371.42"
change="7.66"
change_percent="2.0624%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="44"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="56"
Volume_recent_avg="226618"
Change_recent_avg="0.3"
Delta_recent_avg="7.94"
Variance_recent_avg="3.97"
Change_ratio_recent_avg="0.07"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="56"
Aroon_momentum_negative="44"
image_negative_thumbnail_id_1="1121"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0154.jpeg"
image_negative_thumbnail_id_2="520"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0085.jpeg"
image_neutral_thumbnail_id_1="597"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0002.jpeg"
image_neutral_thumbnail_id_2="589"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0010.jpeg"
image_positive_thumbnail_id_1="606"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0102.jpeg"
image_positive_thumbnail_id_2="685"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0023.jpeg"
image_professor_thumbnail_id_1="1174"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
